 We aimed to determine the efficacy of the 10-valent pneumococcal-Haemophilus influenzae<pathogen> protein D conjugate vaccine ( PHiD-CV) in children aged 18-months to < 18-years with recurrent protracted bacterial bronchitis<symptom> ( rPBB) , chronic suppurative lung disease<disease> ( CSLD) or bronchiectasis. In a multi-centre , double-blind randomised controlled trial , children received two doses , 2-months apart of the 10vPHiD-CV or quadrivalent meningococcal-ACYW